Start triage first, then route to emergency care.
Need urgent help? Start triage first, then route to emergency care.
Roxee Medication Guide
Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.
Veterinary professional?
These are the reference facts Roxee uses on browse cards and quick facts.
Sponsor, product, and application records imported from Animal Drugs @ FDA.
openFDA reaction terms and case summaries are supporting evidence, not proof of causality.
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: Boehringer Ingelheim Animal Health USA Inc.
Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.
To improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. Species commonly shown: Cats.
To improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
Give Senvelgo by mouth once daily at approximately the same time each day, with or without food, as directed by a veterinarian.
Do not use Senvelgo in cats with diabetes mellitus who have previously been treated with insulin, are receiving insulin, or have insulin-dependent diabetes mellitus; do not start it in cats that are anorexic, dehydrated, or lethargic.
Top reported reactions (openFDA): Overdose, Diarrhoea, Vomiting, Hypersalivation, Wound, Dermal cyst(s).
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continueStart here first for the safest next-step summary before the deeper medication detail.
Used for:
To improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
Dosing note:
Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.
What to watch for:
When to call the vet:
What to tell or ask your vet today:
A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.
Roxee has limited cited overview evidence for Velagliflozin Proline Monohydrate; use the official documents and your veterinarian's instructions for product-specific decisions.
32 tracked reaction signals; 32 reported cases; 10 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.
Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.
Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.
Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.
Loss of appetite (1 reports), Haemorrhage NOS (1 reports), Glucosuria (1 reports), Diarrhea (1 reports), Diabetic ketoacidosis (1 reports)
Digestive (5), Behavior (1), Other (26)
Cat (30 reports), Dog (2 reports)
Domestic Shorthair (5), Domestic Longhair (2), ['Domestic Shorthair', 'Cat (unknown)'] (1). These are report metadata, not proof that a breed is at higher risk.
Verify whether Velagliflozin Proline Monohydrate fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.
Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.
Loss of appetite, Haemorrhage NOS, Glucosuria
Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.
Review status / Updated / Sources
Review status: Clinical reviewer not listed
Updated: May 15, 2026, 10:04 AM UTC
Side effects to monitor:
Most reported reactions:
Emergency warning signs:
Source-backed clinical checkpoints for quick review.
Official label facts first, then secondary summaries. Marketing content is separated below.
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.
Received 2026-01-19 · MSK · MSK
Received 2026-01-14 · MSK · MSK
Received 2025-12-18 · MSK · MSK
Received 2025-12-15 · MSK · MSK
Received 2025-12-10 · MSK · MSK
Received 2025-11-20 · MSK · MSK
Tap or hover a reaction to see what it means in plain language.
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Digestive | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Digestive | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 |
Species coverage: Cat (30) Dog (2)
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Digestive | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Digestive | Cat | Non-serious | - | 1 | |
| Digestive | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Digestive | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Digestive | Cat | Non-serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Behavior | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 |
The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.
Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.
Full source previews and metadata remain in the veterinary/professional layer.
Official label / PI · Labeling
Official label / PI · Official label
This source does not expose a safe inline preview. Use the original source link for the full document.
Official FDA veterinary drug portal.
Official label / PI · Safety communication
This source does not expose a safe inline preview. Use the original source link for the full document.
FDA owner-facing guidance for Bexacat and Senvelgo in diabetic cats.
Official label / PI · Safety communication
This source does not expose a safe inline preview. Use the original source link for the full document.
FDA safety communication for veterinarians using Senvelgo.
Official label / PI · Safety communication
This source does not expose a safe inline preview. Use the original source link for the full document.
Official FDA communication referencing Senvelgo and sponsor.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
To improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
Administer orally 0.45 mg per pound of body weight (1 mg per kilogram) velagliflozin once daily.
SPL · Structured Product Label
FOI · FOI
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
Quick facts and links to official labeling and safety signals.
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 0010-4614-01 | 0010 | - | |
| 0010-4614-02 | 0010 | - |
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
Every non-trivial field is expected to include provenance and update timestamps.
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Senvelgo®
RX
Velagliflozin
Solution
• Oral
|
Boehringer Ingelheim Animal Health USA, Inc. | NADA 141-568 | Approved | May 14, 2026 |
Data source: FDA Animal Drugs @ FDA (public search export).
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
To improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
Administer orally 0.45 mg per pound of body weight (1 mg per kilogram) velagliflozin once daily.
FDA page: Open in Animal Drugs @ FDA
To improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
Source: FDA Animal Drugs @ FDA • Reference
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Digestive.
Showing top 5 for Behavior.
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Cat, Domestic Shorthair, Female, 12 year, 4.8 kilogram • Drug: MSK, Solution, Oral, Dose: 1 Milligram per kilogram, Frequency: 1 per day • Reactions: Not eating, Tiredness (lethargy), Ketosis, Hypokalaemia, Weight loss… • Outcome: Ongoing
Cat, Domestic Longhair, Male, 9.42 year, 6.12 kilogram • Drug: MSK, Unknown • Reactions: Weight loss, Tiredness (lethargy), Decreased appetite, Hyperglycaemia, Elevated betahydroxybutyrate… • Outcome: Outcome Unknown
Cat, Domestic Longhair, Male, 6 year, 5.14 kilogram • Drug: MSK, Solution, Oral, Dose: 1 Milligram per kilogram, Frequency: 1 per day • Reactions: Hard stool, Vomiting, Inappropriate defecation • Outcome: Outcome Unknown
Cat, Domestic Shorthair, Male, 13 year, 3.221 kilogram • Drug: MSK, Solution, Oral, Dose: 1 Milligram per kilogram, Frequency: 1 per day • Reactions: Pemphigus foliaceus • Outcome: Outcome Unknown
Cat, ['Domestic Shorthair', 'Cat (unknown)'], Male, 13 year, 4.96 kilogram • Drug: MSK, Oral, Dose: 1 tablet per animal, Frequency: 1 per day • Reactions: Weight loss, Diarrhea, Loss of appetite, Vomiting, Dehydration… • Outcome: Euthanized
Cat, Domestic Shorthair, Male, 10 year, 6.169 kilogram • Drug: MSK, Solution, Oral, Dose: 1 Milligram per kilogram, Frequency: 1 per day • Reactions: Diarrhea, Hypotension, Vomiting, Increased respiratory rate, Weight loss • Outcome: Outcome Unknown
Cat, Domestic Shorthair, Male, 9 year, 4.59 kilogram • Drug: MSK, Solution, Oral, Dose: 1 Milligram per kilogram, Frequency: 1 per day • Reactions: Pulmonary neoplasm, Increased lung sounds, Tachypnoea, Laboured breathing, Weak pulse… • Outcome: Euthanized
Cat, Domestic Shorthair, Male, 7 year, 5.1 kilogram • Drug: MSK, Solution, Oral, Dose: 1 Milligram per kilogram, Frequency: 1 per day • Reactions: Vomiting, Weight gain • Outcome: Outcome Unknown
Data source: FDA openFDA Animal & Veterinary adverse event reports.
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.